

Catapano CV – Publications

1: Civenni G, Albino D, Shinde D, Vázquez R, Merulla J, Kokanovic A, Mapelli SN, Carbone GM, Catapano CV. Transcriptional Reprogramming and Novel Therapeutic Approaches for Targeting Prostate Cancer Stem Cells. *Front Oncol.* 2019 May 9;9:385. doi: 10.3389/fonc.2019.00385. eCollection 2019. Review. PubMed PMID: 31143708; PubMed Central PMCID: PMC6521702.

2: Civenni G, Bosotti R, Timpanaro A, Vázquez R, Merulla J, Pandit S, Rossi S, Albino D, Allegrini S, Mitra A, Mapelli SN, Vierling L, Giurdanella M, Marchetti M, Paganoni A, Rinaldi A, Losa M, Mira-Catò E, D'Antuono R, Morone D, Rezai K, D'Ambrosio G, Ouafik L, Mackenzie S, Riveiro ME, Cvitkovic E, Carbone GM, Catapano CV. Epigenetic Control of Mitochondrial Fission Enables Self-Renewal of Stem-like Tumor Cells in Human Prostate Cancer. *Cell Metab.* 2019 May 20. pii: S1550-4131(19)30244-X. doi: 10.1016/j.cmet.2019.05.004. [Epub ahead of print] PubMed PMID: 31130467.

3: Scimeca M, Urbano N, Bonfiglio R, Mapelli SN, Catapano CV, Carbone GM, Ciuffa S, Tavolozza M, Schillaci O, Mauriello A, Bonanno E. Prostate Osteoblast-Like Cells: A Reliable Prognostic Marker of Bone Metastasis in Prostate Cancer Patients. *Contrast Media Mol Imaging.* 2018 Dec 9;2018:9840962. doi: 10.1155/2018/9840962. eCollection 2018. Erratum in: *Contrast Media Mol Imaging.* 2019 Mar 11;2019:7843735. PubMed PMID: 30627063; PubMed Central PMCID: PMC6305022.

4: Mapelli SN, Napoli S, Pisignano G, Garcia-Escudero R, Carbone GM, Catapano CV. Deciphering the complexity of human noncoding promoter-proximal transcriptome. *Bioinformatics.* 2018 Dec 10. doi: 10.1093/bioinformatics/bty981. [Epub ahead of print] PubMed PMID: 30535182.

5: Civenni G, Carbone GM, Catapano CV. Overview of Genetically Engineered Mouse Models of Prostate Cancer and Their Applications in Drug Discovery. *Curr Protoc Pharmacol*. 2018 Jun;81(1):e39. doi: 10.1002/cpph.39. Epub 2018 Jun 7. Review. PubMed PMID: 29927081.

6: Sgrignani J, Garofalo M, Matkovic M, Merulla J, Catapano CV, Cavalli A. Structural Biology of STAT3 and Its Implications for Anticancer Therapies Development. *Int J Mol Sci*. 2018 May 28;19(6). pii: E1591. doi: 10.3390/ijms19061591. Review. PubMed PMID: 29843450; PubMed Central PMCID: PMC6032208.

7: Chen J, Guccini I, Di Mitri D, Brina D, Revandkar A, Sarti M, Pasquini E, Alajati A, Pinton S, Losa M, Civenni G, Catapano CV, Sgrignani J, Cavalli A, D'Antuono R, Asara JM, Morandi A, Chiarugi P, Crotti S, Agostini M, Montopoli M, Masgras I, Rasola A, Garcia-Escudero R, Delaleu N, Rinaldi A, Bertoni F, Bono J, Carracedo A, Alimonti A. Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer. *Nat Genet*. 2018 Feb;50(2):219-228. doi: 10.1038/s41588-017-0026-3. Epub 2018 Jan 15. Erratum in: *Nat Genet*. 2018 Sep;50(9):1343. PubMed PMID: 29335542; PubMed Central PMCID: PMC5810912.

8: Janouskova H, El Tekle G, Bellini E, Udeshi ND, Rinaldi A, Ulbricht A, Bernasocchi T, Civenni G, Losa M, Svinkina T, Bielski CM, Kryukov GV, Cascione L, Napoli S, Enchev RI, Mutch DG, Carney ME, Berchuck A, Winterhoff BJN, Broaddus RR, Schraml P, Moch H, Bertoni F, Catapano CV, Peter M, Carr SA, Garraway LA, Wild PJ, Theurillat JP. Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors. *Nat Med*. 2017

Sep;23(9):1046-1054. doi: 10.1038/nm.4372. Epub 2017 Aug 14. PubMed PMID: 28805821; PubMed Central PMCID: PMC5592092.

9: Napoli S, Piccinelli V, Mapelli SN, Pisignano G, Catapano CV. Natural antisense transcripts drive a regulatory cascade controlling c-MYC transcription. *RNA Biol.* 2017 Dec 2;14(12):1742-1755. doi: 10.1080/15476286.2017.1356564. Epub 2017 Oct 11. PubMed PMID: 28805496; PubMed Central PMCID: PMC5731802.

10: Genini D, Brambilla L, Laurini E, Merulla J, Civenni G, Pandit S, D'Antuono R, Perez L, Levy DE, Prici S, Carbone GM, Catapano CV. Mitochondrial dysfunction induced by a SH2 domain-targeting STAT3 inhibitor leads to metabolic synthetic lethality in cancer cells. *Proc Natl Acad Sci U S A.* 2017 Jun 20;114(25):E4924-E4933. doi: 10.1073/pnas.1615730114. Epub 2017 Jun 5. PubMed PMID: 28584133; PubMed Central PMCID: PMC5488915.

11: Pisignano G, Napoli S, Magistri M, Mapelli SN, Pastori C, Di Marco S, Civenni G, Albino D, Enriquez C, Allegrini S, Mitra A, D'Ambrosio G, Mello-Grand M, Chiorino G, Garcia-Escudero R, Varani G, Carbone GM, Catapano CV. A promoter-proximal transcript targeted by genetic polymorphism controls E-cadherin silencing in human cancers. *Nat Commun.* 2017 May 30;8:15622. doi: 10.1038/ncomms15622. PubMed PMID: 28555645; PubMed Central PMCID: PMC5459991.

12: Stathis A, Hess D, von Moos R, Homicsko K, Griguolo G, Joerger M, Mark M, Ackermann CJ, Allegrini S, Catapano CV, Xyrafas A, Enoiu M, Berardi S, Gargiulo P, Sessa C; Swiss Group for Clinical Cancer Research (SAKK). Phase I trial of the oral smoothed inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors. *Invest New Drugs.* 2017 Dec;35(6):766-772. doi: 10.1007/s10637-017-0454-z. Epub 2017 Mar 20. PubMed PMID: 28317088.

13: Dallavalle C, Albino D, Civenni G, Merulla J, Ostano P, Mello-Grand M, Rossi S, Losa M, D'Ambrosio G, Sessa F, Thalmann GN, Garcia-Escudero R, Zitella A, Chiorino G, Catapano CV, Carbone GM. MicroRNA-424 impairs ubiquitination to activate STAT3 and promote prostate tumor progression. *J Clin Invest*. 2016 Dec 1;126(12):4585-4602. doi: 10.1172/JCI86505. Epub 2016 Nov 7. PubMed PMID: 27820701; PubMed Central PMCID: PMC5127674.

14: Rabi T, Catapano CV. Aphanin, a triterpenoid from *Amoora rohituka* inhibits K-Ras mutant activity and STAT3 in pancreatic carcinoma cells. *Tumour Biol*. 2016 Sep;37(9):12455-12464. Epub 2016 Jun 22. PubMed PMID: 27333990.

15: Roos M, Pradère U, Ngondo RP, Behera A, Allegrini S, Civenni G, Zagalak JA, Marchand JR, Menzi M, Towbin H, Scheuermann J, Neri D, Caflich A, Catapano CV, Ciaudo C, Hall J. A Small-Molecule Inhibitor of Lin28. *ACS Chem Biol*. 2016 Oct 21;11(10):2773-2781. Epub 2016 Aug 22. PubMed PMID: 27548809.

16: Albino D, Civenni G, Rossi S, Mitra A, Catapano CV, Carbone GM. The ETS factor ESE3/EHF represses IL-6 preventing STAT3 activation and expansion of the prostate cancer stem-like compartment. *Oncotarget*. 2016 Nov 22;7(47):76756-76768. doi: 10.18632/oncotarget.12525. PubMed PMID: 27732936; PubMed Central PMCID: PMC5363547.

17: Albino D, Civenni G, Dallavalle C, Roos M, Jahns H, Curti L, Rossi S, Pinton S, D'Ambrosio G, Sessa F, Hall J, Catapano CV, Carbone GM. Activation of the Lin28/let-7 Axis by Loss of ESE3/EHF Promotes a Tumorigenic and Stem-like Phenotype in Prostate Cancer. *Cancer Res*. 2016 Jun 15;76(12):3629-43. doi:

10.1158/0008-5472.CAN-15-2665. Epub 2016 May 2. PubMed PMID: 27197175.

18: Civenni G, Longoni N, Costales P, Dallavalle C, García Inclán C, Albino D, Nuñez LE, Morís F, Carbone GM, Catapano CV. EC-70124, a Novel Glycosylated Indolocarbazole Multikinase Inhibitor, Reverts Tumorigenic and Stem Cell Properties in Prostate Cancer by Inhibiting STAT3 and NF- κ B. *Mol Cancer Ther.* 2016 May;15(5):806-18. doi: 10.1158/1535-7163.MCT-15-0791. Epub 2016 Jan 29. PubMed PMID: 26826115.

19: Sgrignani J, Olsson S, Ekonomiuk D, Genini D, Krause R, Catapano CV, Cavalli A. Molecular Determinants for Unphosphorylated STAT3 Dimerization Determined by Integrative Modeling. *Biochemistry.* 2015 Sep 8;54(35):5489-501. doi: 10.1021/bi501529x. Epub 2015 Aug 25. PubMed PMID: 26283080.

20: Kalathur M, Toso A, Chen J, Revandkar A, Danzer-Baltzer C, Guccini I, Alajati A, Sarti M, Pinton S, Brambilla L, Di Mitri D, Carbone G, Garcia-Escudero R, Padova A, Magnoni L, Tarditi A, Maccari L, Malusa F, Kalathur RK, A Pinna L, Cozza G, Ruzzene M, Delaleu N, Catapano CV, Frew IJ, Alimonti A. A chemogenomic screening identifies CK2 as a target for pro-senescence therapy in PTEN-deficient tumours. *Nat Commun.* 2015 Jun 18;6:7227. doi: 10.1038/ncomms8227. PubMed PMID: 26085373.

21: Alajati A, Guccini I, Pinton S, Garcia-Escudero R, Bernasocchi T, Sarti M, Montani E, Rinaldi A, Montemurro F, Catapano C, Bertoni F, Alimonti A. Interaction of CDCP1 with HER2 enhances HER2-driven tumorigenesis and promotes trastuzumab resistance in breast cancer. *Cell Rep.* 2015 Apr 28;11(4):564-76. doi: 10.1016/j.celrep.2015.03.044. Epub 2015 Apr 16. PubMed PMID: 25892239.

22: Brambilla L, Genini D, Laurini E, Merulla J, Perez L, Fermeglia M, Carbone GM, Pricl S, Catapano CV. Hitting the right spot: Mechanism of action of OPB-31121, a novel and potent inhibitor of the Signal Transducer and Activator of Transcription 3 (STAT3). *Mol Oncol*. 2015 Jun;9(6):1194-206. doi: 10.1016/j.molonc.2015.02.012. Epub 2015 Mar 5. PubMed PMID: 25777967; PubMed Central PMCID: PMC5528765.

23: Roos M, Rebhan MA, Lucic M, Pavlicek D, Pradere U, Towbin H, Civenni G, Catapano CV, Hall J. Short loop-targeting oligoribonucleotides antagonize Lin28 and enable pre-let-7 processing and suppression of cell growth in let-7-deficient cancer cells. *Nucleic Acids Res*. 2015 Jan;43(2):e9. doi: 10.1093/nar/gku1090. Epub 2014 Nov 6. PubMed PMID: 25378324; PubMed Central PMCID: PMC4333367.

24: Toso A, Revandkar A, Di Mitri D, Guccini I, Proietti M, Sarti M, Pinton S, Zhang J, Kalathur M, Civenni G, Jarrossay D, Montani E, Marini C, Garcia-Escudero R, Scanziani E, Grassi F, Pandolfi PP, Catapano CV, Alimonti A. Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity. *Cell Rep*. 2014 Oct 9;9(1):75-89. doi: 10.1016/j.celrep.2014.08.044. Epub 2014 Sep 25. PubMed PMID: 25263564.

25: Di Mitri D, Toso A, Chen JJ, Sarti M, Pinton S, Jost TR, D'Antuono R, Montani E, Garcia-Escudero R, Guccini I, Da Silva-Alvarez S, Collado M, Eisenberger M, Zhang Z, Catapano C, Grassi F, Alimonti A. Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer. *Nature*. 2014 Nov 6;515(7525):134-7. doi: 10.1038/nature13638. Epub 2014 Aug 24. PubMed PMID: 25156255.

26: Civenni G, Malek A, Albino D, Garcia-Escudero R, Napoli S, Di Marco S, Pinton

S, Sarti M, Carbone GM, Catapano CV. RNAi-mediated silencing of Myc transcription inhibits stem-like cell maintenance and tumorigenicity in prostate cancer. *Cancer Res.* 2013 Nov 15;73(22):6816-27. doi: 10.1158/0008-5472.CAN-13-0615. Epub 2013 Sep 24. PubMed PMID: 24063893.

27: Liu X, Liu C, Catapano CV, Peng L, Zhou J, Rocchi P. Structurally flexible triethanolamine-core poly(amidoamine) dendrimers as effective nanovectors to deliver RNAi-based therapeutics. *Biotechnol Adv.* 2014 Jul-Aug;32(4):844-52. doi: 10.1016/j.biotechadv.2013.08.001. Epub 2013 Aug 9. Review. PubMed PMID: 23938269.

28: Sarti M, Pinton S, Limoni C, Carbone GM, Pagani O, Cavalli F, Catapano CV. Differential expression of testin and survivin in breast cancer subtypes. *Oncol Rep.* 2013 Aug;30(2):824-32. doi: 10.3892/or.2013.2502. Epub 2013 May 28. PubMed PMID: 23715752.

29: Longoni N, Sarti M, Albino D, Civenni G, Malek A, Ortelli E, Pinton S, Mello-Grand M, Ostano P, D'Ambrosio G, Sessa F, Garcia-Escudero R, Thalmann GN, Chiorino G, Catapano CV, Carbone GM. ETS transcription factor ESE1/ELF3 orchestrates a positive feedback loop that constitutively activates NF- κ B and drives prostate cancer progression. *Cancer Res.* 2013 Jul 15;73(14):4533-47. doi: 10.1158/0008-5472.CAN-12-4537. Epub 2013 May 16. PubMed PMID: 23687337.

30: Malek A, Gyorffy B, Catapano CV, Schäfer R. Selection of optimal combinations of target genes for therapeutic multi-gene silencing based on miRNA co-regulation. *Cancer Gene Ther.* 2013 May;20(5):326-9. doi: 10.1038/cgt.2013.20. Epub 2013 Apr 26. PubMed PMID: 23618947.

31: Genini D, Garcia-Escudero R, Carbone GM, Catapano CV. Transcriptional and Non-Transcriptional Functions of PPAR β/δ in Non-Small Cell Lung Cancer. *PLoS One*. 2012;7(9):e46009. doi: 10.1371/journal.pone.0046009. Epub 2012 Sep 25. PubMed PMID: 23049921; PubMed Central PMCID: PMC3457940.

32: Longoni N, Kunderfranco P, Pellini S, Albino D, Mello-Grand M, Pinton S, D'Ambrosio G, Sarti M, Sessa F, Chiorino G, Catapano CV, Carbone GM. Aberrant expression of the neuronal-specific protein DCDC2 promotes malignant phenotypes and is associated with prostate cancer progression. *Oncogene*. 2013 May 2;32(18):2315-24, 2324.e1-4. doi: 10.1038/onc.2012.245. Epub 2012 Jun 25. PubMed PMID: 22733135.

33: Parma G, Mancari R, Del Conte G, Scambia G, Gadducci A, Hess D, Katsaros D, Sessa C, Rinaldi A, Bertoni F, Vitali A, Catapano CV, Marsoni S, van de Velde H, Colombo N. An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens. *Int J Gynecol Cancer*. 2012 Jun;22(5):792-800. doi: 10.1097/IGC.0b013e318251051a. PubMed PMID: 22635029.

34: Malek A, Núñez LE, Magistri M, Brambilla L, Jovic S, Carbone GM, Morís F, Catapano CV. Modulation of the activity of Sp transcription factors by mithramycin analogues as a new strategy for treatment of metastatic prostate cancer. *PLoS One*. 2012;7(4):e35130. doi: 10.1371/journal.pone.0035130. Epub 2012 Apr 19. PubMed PMID: 22545098; PubMed Central PMCID: PMC3334962.

35: Albino D, Longoni N, Curti L, Mello-Grand M, Pinton S, Civenni G, Thalmann G, D'Ambrosio G, Sarti M, Sessa F, Chiorino G, Catapano CV, Carbone GM. ESE3/EHF controls epithelial cell differentiation and its loss leads to prostate tumors

with mesenchymal and stem-like features. *Cancer Res.* 2012 Jun 1;72(11):2889-900. doi: 10.1158/0008-5472.CAN-12-0212. Epub 2012 Apr 13. PubMed PMID: 22505649.

36: Babbio F, Pistore C, Curti L, Castiglioni I, Kunderfranco P, Brino L, Oudet P, Seiler R, Thalman GN, Roggero E, Sarti M, Pinton S, Mello-Grand M, Chiorino G, Catapano CV, Carbone GM, Bonapace IM. The SRA protein UHRF1 promotes epigenetic crosstalks and is involved in prostate cancer progression. *Oncogene.* 2012 Nov 15;31(46):4878-87. doi: 10.1038/onc.2011.641. Epub 2012 Feb 13. PubMed PMID: 22330138.

37: Pandey R, Mehrotra D, Catapano C, Choubey V, Sarin R, Mahdi AA, Singh S. Association of mitochondrial deoxyribonucleic acid mutation with polymorphism in CYP2E1 gene in oral carcinogenesis. *J Oral Biol Craniofac Res.* 2012 Jan-Apr;2(1):4-9. doi: 10.1016/S2212-4268(12)60003-7. PubMed PMID: 25756024; PubMed Central PMCID: PMC3941659.

38: Capobianco ML, Catapano CV. Daunomycin-TFO Conjugates for Downregulation of Gene Expression. *Top Curr Chem.* 2008;283:45-71. doi: 10.1007/128_2007_2. PubMed PMID: 23605628.

39: Cangemi R, Mensah A, Albertini V, Jain A, Mello-Grand M, Chiorino G, Catapano CV, Carbone GM. Reduced expression and tumor suppressor function of the ETS transcription factor ESE-3 in prostate cancer. *Oncogene.* 2008 May 1;27(20):2877-85. Epub 2007 Nov 26. PubMed PMID: 18037958.

40: Rinaldi A, Poretti G, Kwee I, Zucca E, Catapano CV, Tibiletti MG, Bertoni F. Concomitant MYC and microRNA cluster miR-17-92 (C13orf25) amplification in human

mantle cell lymphoma. *Leuk Lymphoma*. 2007 Feb;48(2):410-2. PubMed PMID: 17325905.

41: Lacrima K, Rinaldi A, Vignati S, Martin V, Tibiletti MG, Gaidano G, Catapano CV, Bertoni F. Cyclin-dependent kinase inhibitor seliciclib shows in vitro activity in diffuse large B-cell lymphomas. *Leuk Lymphoma*. 2007 Jan;48(1):158-67. PubMed PMID: 17325859.

42: Genini D, Catapano CV. Block of nuclear receptor ubiquitination. A mechanism of ligand-dependent control of peroxisome proliferator-activated receptor delta activity. *J Biol Chem*. 2007 Apr 20;282(16):11776-85. Epub 2007 Feb 26. PubMed PMID: 17324937.

43: Genini D, Catapano CV. Control of peroxisome proliferator-activated receptor fate by the ubiquitin-proteasome system. *J Recept Signal Transduct Res*. 2006;26(5-6):679-92. Review. PubMed PMID: 17118805.

44: Vignati S, Albertini V, Rinaldi A, Kwee I, Riva C, Oldrini R, Capella C, Bertoni F, Carbone GM, Catapano CV. Cellular and molecular consequences of peroxisome proliferator-activated receptor-gamma activation in ovarian cancer cells. *Neoplasia*. 2006 Oct;8(10):851-61. PubMed PMID: 17032502; PubMed Central PMCID: PMC1715924.

45: Pucci D, Albertini V, Bloise R, Bellusci A, Cataldi A, Catapano CV, Ghedini M, Crispini A. Synthesis and anticancer activity of cyclopalladated complexes containing 4-hydroxy-acridine. *J Inorg Biochem*. 2006 Sep;100(9):1575-8. Epub 2006 May 5. PubMed PMID: 16828871.

46: Rinaldi A, Kwee I, Poretti G, Mensah A, Pruneri G, Capello D, Rossi D, Zucca E, Ponzoni M, Catapano C, Tibiletti MG, Paulli M, Gaidano G, Bertoni F. Comparative genome-wide profiling of post-transplant lymphoproliferative disorders and diffuse large B-cell lymphomas. *Br J Haematol.* 2006 Jul;134(1):27-36. PubMed PMID: 16803564.

47: Albertini V, Jain A, Vignati S, Napoli S, Rinaldi A, Kwee I, Nur-e-Alam M, Bergant J, Bertoni F, Carbone GM, Rohr J, Catapano CV. Novel GC-rich DNA-binding compound produced by a genetically engineered mutant of the mithramycin producer *Streptomyces argillaceus* exhibits improved transcriptional repressor activity: implications for cancer therapy. *Nucleic Acids Res.* 2006 Mar 29;34(6):1721-34. Print 2006. PubMed PMID: 16571899; PubMed Central PMCID: PMC1420802.

48: Napoli S, Negri U, Arcamone F, Capobianco ML, Carbone GM, Catapano CV. Growth inhibition and apoptosis induced by daunomycin-conjugated triplex-forming oligonucleotides targeting the c-myc gene in prostate cancer cells. *Nucleic Acids Res.* 2006 Jan 30;34(2):734-44. Print 2006. PubMed PMID: 16449206; PubMed Central PMCID: PMC1356532.

49: Rinaldi A, Kwee I, Taborelli M, Largo C, Uccella S, Martin V, Poretti G, Gaidano G, Calabrese G, Martinelli G, Baldini L, Pruneri G, Capella C, Zucca E, Cotter FE, Cigudosa JC, Catapano CV, Tibiletti MG, Bertoni F. Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. *Br J Haematol.* 2006 Feb;132(3):303-16. PubMed PMID: 16409295.

50: Napoli S, Carbone GM, Catapano CV, Shaw N, Arya DP. Neomycin improves

cationic lipid-mediated transfection of DNA in human cells. *Bioorg Med Chem Lett*. 2005 Jul 15;15(14):3467-9. PubMed PMID: 15950473.

51: Lacrima K, Valentini A, Lambertini C, Taborelli M, Rinaldi A, Zucca E, Catapano C, Cavalli F, Gianella-Borradori A, Maccallum DE, Bertoni F. In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas. *Ann Oncol*. 2005 Jul;16(7):1169-76. Epub 2005 Apr 25. PubMed PMID: 15851403.

52: Carbone GM, Napoli S, Valentini A, Cavalli F, Watson DK, Catapano CV. Triplex DNA-mediated downregulation of Ets2 expression results in growth inhibition and apoptosis in human prostate cancer cells. *Nucleic Acids Res*. 2004 Aug 16;32(14):4358-67. Print 2004. PubMed PMID: 15314206; PubMed Central PMCID: PMC514370.

53: Rocha Lima CM, Catapano CV, Pacheco D, Sherman CA, Oakhill G, Mushtaq C, Freeman KD, Green MR. A phase I study of sequential administration of escalating doses of intravenous paclitaxel, oral topotecan, and fixed-dose oral etoposide in patients with solid tumors. *Cancer*. 2004 Jun 15;100(12):2671-9. PubMed PMID: 15197811.

54: Carbone GM, McGuffie E, Napoli S, Flanagan CE, Dembech C, Negri U, Arcamone F, Capobianco ML, Catapano CV. DNA binding and antigene activity of a daunomycin-conjugated triplex-forming oligonucleotide targeting the P2 promoter of the human c-myc gene. *Nucleic Acids Res*. 2004 Apr 30;32(8):2396-410. Print 2004. PubMed PMID: 15121897; PubMed Central PMCID: PMC419437.

55: Remsing LL, Bahadori HR, Carbone GM, McGuffie EM, Catapano CV, Rohr J. Inhibition of c-src transcription by mithramycin: structure-activity relationships of biosynthetically produced mithramycin analogues using the c-src promoter as target. *Biochemistry*. 2003 Jul 15;42(27):8313-24. PubMed PMID: 12846580.

56: Carbone GM, McGuffie EM, Collier A, Catapano CV. Selective inhibition of transcription of the Ets2 gene in prostate cancer cells by a triplex-forming oligonucleotide. *Nucleic Acids Res*. 2003 Feb 1;31(3):833-43. PubMed PMID: 12560478; PubMed Central PMCID: PMC149218.

57: McGuffie EM, Catapano CV. Design of a novel triple helix-forming oligodeoxyribonucleotide directed to the major promoter of the c-myc gene. *Nucleic Acids Res*. 2002 Jun 15;30(12):2701-9. PubMed PMID: 12060688; PubMed Central PMCID: PMC117288.

58: Bahadori HR, Green MR, Catapano CV. Synergistic interaction between topotecan and microtubule-interfering agents. *Cancer Chemother Pharmacol*. 2001 Sep;48(3):188-96. PubMed PMID: 11592339.

59: Carbone GM, Catapano CV, Fernandes DJ. Imbalanced DNA synthesis induced by cytosine arabinoside and fludarabine in human leukemia cells. *Biochem Pharmacol*. 2001 Jul 1;62(1):101-10. PubMed PMID: 11377401.

60: McGuffie EM, Pacheco D, Carbone GM, Catapano CV. Antigenic and antiproliferative effects of a c-myc-targeting phosphorothioate triple helix-forming oligonucleotide in human leukemia cells. *Cancer Res*. 2000 Jul

15;60(14):3790-9. PubMed PMID: 10919652.

61: Catapano CV, McGuffie EM, Pacheco D, Carbone GM. Inhibition of gene expression and cell proliferation by triple helix-forming oligonucleotides directed to the c-myc gene. *Biochemistry*. 2000 May 2;39(17):5126-38. PubMed PMID: 10819980.

62: Erba E, Bergamaschi D, Ronzoni S, Faretta M, Taverna S, Bonfanti M, Catapano CV, Faircloth G, Jimeno J, D'Incalci M. Mode of action of thiocoraline, a natural marine compound with anti-tumour activity. *Br J Cancer*. 1999 Jun;80(7):971-80. PubMed PMID: 10362104; PubMed Central PMCID: PMC2363046.

63: Catapano CV, Carbone GM, Pisani F, Qiu J, Fernandes DJ. Arrest of replication fork progression at sites of topoisomerase II-mediated DNA cleavage in human leukemia CEM cells incubated with VM-26. *Biochemistry*. 1997 May 13;36(19):5739-48. PubMed PMID: 9153414.

64: Qiu J, Catapano CV, Fernandes DJ. Formation of topoisomerase II alpha complexes with nascent DNA is related to VM-26-induced cytotoxicity. *Biochemistry*. 1996 Dec 17;35(50):16354-60. PubMed PMID: 8973211.

65: Catapano CV, Carbone GM, Fernandes DJ. The nuclear matrix as a target for cancer therapy. *Ann Oncol*. 1996 Sep;7(7):659-66. Review. PubMed PMID: 8905022.

66: Lorico A, Rappa G, Srimatkandada S, Catapano CV, Fernandes DJ, Germino JF, Sartorelli AC. Increased rate of adenosine triphosphate-dependent etoposide

(VP-16) efflux in a murine leukemia cell line overexpressing the multidrug resistance-associated protein (MRP) gene. *Cancer Res.* 1995 Oct 1;55(19):4352-60. PubMed PMID: 7671247.

67: Catapano CV, Dayton JS, Mitchell BS, Fernandes DJ. GTP depletion induced by IMP dehydrogenase inhibitors blocks RNA-primed DNA synthesis. *Mol Pharmacol.* 1995 May;47(5):948-55. PubMed PMID: 7746281.

68: Fernandes DJ, Catapano CV. The nuclear matrix as a site of anticancer drug action. *Int Rev Cytol.* 1995;162A:539-76. Review. PubMed PMID: 8575887.

69: Fernandes DJ, Qiu J, Catapano CV. DNA topoisomerase II isozymes involved in anticancer drug action and resistance. *Adv Enzyme Regul.* 1995;35:265-81. PubMed PMID: 7572348.

70: Danks MK, Qiu J, Catapano CV, Schmidt CA, Beck WT, Fernandes DJ. Subcellular distribution of the alpha and beta topoisomerase II-DNA complexes stabilized by VM-26. *Biochem Pharmacol.* 1994 Nov 1;48(9):1785-95. PubMed PMID: 7980648.

71: Limonta M, Colombo T, Damia G, Catapano CV, Conter V, Gervasoni M, Masera G, Liso V, Specchia G, Giudici G, et al. Cytotoxic activity and mechanism of action of 5-Aza-2'-deoxycytidine in human CML cells. *Leuk Res.* 1993 Nov;17(11):977-82. PubMed PMID: 7694001.

72: Catapano CV, Perrino FW, Fernandes DJ. Primer RNA chain termination induced by 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-triphosphate. A mechanism of DNA

synthesis inhibition. J Biol Chem. 1993 Apr 5;268(10):7179-85. PubMed PMID: 7681821.

73: Taverna P, Catapano CV, Citti L, Bonfanti M, D'Incalci M. Influence of O6-methylguanine on DNA damage and cytotoxicity of temozolomide in L1210 mouse leukemia sensitive and resistant to chloroethylnitrosoureas. Anticancer Drugs. 1992 Aug;3(4):401-5. PubMed PMID: 1421437.

74: Catapano CV, Chandler KB, Fernandes DJ. Inhibition of primer RNA formation in CCRF-CEM leukemia cells by fludarabine triphosphate. Cancer Res. 1991 Apr 1;51(7):1829-35. PubMed PMID: 1706219.

75: Fernandes DJ, Catapano CV. Nuclear matrix targets for anticancer agents. Cancer Cells. 1991 Apr;3(4):134-40. Review. PubMed PMID: 1652999.

76: D'Incalci M, Taverna P, Erba E, Filippeschi S, Potenza D, Mariani L, Citti L, Catapano CV. O6-methylguanine and temozolomide can reverse the resistance to chloroethylnitrosoureas of a mouse L1210 leukemia. Anticancer Res. 1991 Jan-Feb;11(1):115-21. PubMed PMID: 2018345.

77: Limonta M, Ubezio P, Catapano CV, Conter V, Costato C, Masera G, Specchia G, Liso V, Barbui T, Giudici G, et al. Doxorubicin and m-AMSA induced DNA damage in blast cells from AML patients. Leuk Res. 1991;15(1):19-24. PubMed PMID: 1997742.

78: Limonta M, Biondi A, Giudici G, Specchia G, Catapano C, Masera G, Barbui T, D'Incalci M. Cytotoxicity and DNA damage caused by 4-demethoxydaunorubicin and

its metabolite 4-demethoxy-13-hydroxydaunorubicin in human acute myeloid leukemia cells. *Cancer Chemother Pharmacol.* 1990;26(5):340-2. PubMed PMID: 2208574.

79: Zucchetti M, Catapano CV, Filippeschi S, Erba E, D'Incalci M. Temozolomide induced differentiation of K562 leukemia cells is not mediated by gene hypomethylation. *Biochem Pharmacol.* 1989 Jul 1;38(13):2069-75. PubMed PMID: 2660797.

80: Citti L, Mariani L, Catapano CV, Malvaldi G. The relevance of DNA repair in the cytotoxic response of mammalian cells to alkylating agents. *Ann Ist Super Sanita.* 1989;25(1):5-9. PubMed PMID: 2751197.

81: Catapano CV, Guaitani A, Brogginì M, Corada M, Bartosek I, Italia C, Donelli MG. Hepatobiliary metabolism and urinary excretion of 4-demethoxydaunorubicin as compared to daunorubicin in rats. *Anticancer Res.* 1988 Jul-Aug;8(4):725-31. PubMed PMID: 3178163.

82: Catapano CV, Ubezio P, Rossi V, Conter V, Jancovich M, D'Incalci M. Intracellular drug concentration and DNA damage in human childhood leukemic cells exposed to doxorubicin. *Biochem Pharmacol.* 1988 May 1;37(9):1863-4. PubMed PMID: 3377855.

83: Donelli MG, Dolfini E, Catapano C, Finazzi M, Mandelli GC, Volontè M, Fuhrman Conti AM. Studies on the biology, histology and cytogenetics of two sublines of a murine ovarian reticular cell sarcoma : Biology of M5 and R16 murine tumor. *Cytotechnology.* 1987 Oct;1(1):87-90. doi: 10.1007/BF00351130. PubMed PMID: 22358448.

84: Catapano CV, Broggin M, Erba E, Ponti M, Mariani L, Citti L, D'Incalci M. In vitro and in vivo methazolastone-induced DNA damage and repair in L-1210 leukemia sensitive and resistant to chloroethylnitrosoureas. *Cancer Res.* 1987 Sep 15;47(18):4884-9. PubMed PMID: 3621181.